ChartMill assigns a Buy % Consensus number of 80% to OMDA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-13 | BMO Capital | Initiate | Outperform |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-07 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-07 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-22 | Barclays | Maintains | Overweight -> Overweight |
| 2025-09-05 | Baird | Initiate | Neutral |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-07-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-01 | Needham | Initiate | Buy |
| 2025-07-01 | Barclays | Initiate | Overweight |
| 2025-07-01 | JP Morgan | Initiate | Overweight |
| 2025-07-01 | Canaccord Genuity | Initiate | Buy |
| 2025-07-01 | Goldman Sachs | Initiate | Buy |
| 2025-07-01 | Morgan Stanley | Initiate | Overweight |
15 analysts have analysed OMDA and the average price target is 29.48 USD. This implies a price increase of 61.97% is expected in the next year compared to the current price of 18.2.
The consensus rating for OMADA HEALTH INC (OMDA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering OMADA HEALTH INC (OMDA) is 15.